甲基转移酶 METTL3 在前列腺癌中的作用：一个潜在的治疗靶点。

First Clinical College, Gannan Medical University, Ganzhou, 341000, China.

Department of Urology, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China.

BMC Cancer. 2024 Jan 2;24(1):8. doi: 10.1186/s12885-023-11741-1.

The incidence of prostate cancer (PCa), the most prevalent malignancy, is currently at the forefront. RNA modification is a subfield of the booming field of epigenetics. To date, more than 170 types of RNA modifications have been described, and N6-methyladenosine (m6A) is the most abundant and well-characterized internal modification of mRNAs involved in various aspects of cancer progression. METTL3, the first identified key methyltransferase, regulates human mRNA and non-coding RNA expression in an m6A-dependent manner. This review elucidates the biological function and role of METTL3 in PCa and discusses the implications of METTL3 as a potential therapeutic target for future research directions and clinical applications.

前列腺癌（PCa）是最常见的恶性肿瘤，其发病率目前处于前列。RNA 修饰是蓬勃发展的表观遗传学领域的一个分支。迄今为止，已经描述了超过 170 种 RNA 修饰类型，而 N6-甲基腺苷（m6A）是参与癌症进展各个方面的 mRNA 中最丰富和特征最明显的内部修饰。METTL3 是第一个被鉴定的关键甲基转移酶，以 m6A 依赖的方式调节人类 mRNA 和非编码 RNA 的表达。本综述阐明了 METTL3 在 PCa 中的生物学功能和作用，并讨论了 METTL3 作为未来研究方向和临床应用的潜在治疗靶点的意义。